Gapping up
In reaction to earnings/guidance:
- JWN +30.2%, SOFI +15.4%, CDLX +12.7%, SGMS +11.4% (also to be rebranded as "Light & Wonder"; also expects to significantly de-lever; also authorizes $750 mln share buyback), ARLO +10.4%, DOMO +10.2% (also CEO Josh James steps down; names John Mellor as CEO), RGNX +9.6%, PLBY +9.4%, JAMF +8.6%, ZIP +8.6% (also announces $100 mln share repurchase authorization), ROST +6.3% (also authorizes $1.9 bln for share repurchases; increases dividend by 9%), HPE +5.6%, PETQ +4.9%, CRM +4%, PLUG +2.1%, LAC +2%, AMC +1.9%, WW +1.8%, JAZZ +1.8%, GRWG +1.1%
Other news:
- SNDX +12.1% (provides clinical update; enrollment remains on track for SNDX-5613 and axatilimab; topline data expected starting in 1H23)
- PLBY +9.4% (to delay 10-K filing)
- ADAG +8.4% (enters license agreement with Sanofi (SNY) to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi)
- FLGC +7.7% (signed a distribution agreement with Florida-based Speedy Distribution )
- HARP +3.3% (receives FDA Fast Track Designation for HPN217)
- F +3.1% (plans Wednesday announcement about acceleration of ambitious Ford+ plan for growth and value creation)
- AMRX +2.3% (FDA approves BLA for filgrastim-ayow)
- SWX +2% (to separate out subsidiary Centuri Group )
- HAL +1.9% (opens oilfield specialty chemical manufacturing reaction facility in Saudi Arabia)
- HES +1.7% (increases dividend, updates Q1 and FY production costs, and reaffirms Q4 production guidance)
- XOM +1.5% (is planning a hydrogen production plant and one of the world's largest carbon capture and storage projects at its integrated refining and petrochemical site at Baytown, Texas)
- SNAP +1.2% (is halting advertising sales to all Russian and Belarusian entities)
Analyst comments:
- DNA +4.2% (resumed with an Outperform at Cowen)
- AI +3.4% (upgraded to Neutral from Underweight at JP Morgan)
- ACVA +3% (upgraded to Overweight from Equal-Weight at Stephens)
- ZS +2.3% (upgraded to Buy from Underperform at Daiwa)